AVTX — AVALO THERAPEUTICS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About AVALO THERAPEUTICS INC (AVTX)
AVALO THERAPEUTICS INC (AVTX) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Steve Cohen (Point72 Asset Management), valued at $14M. Across recent filings, tracked investors recorded 6 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in AVTX
How many top investors track AVTX
A small number of top investors own this.
AVTX Ownership Composition
How AVALO THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Other54.5%
- Hedge Funds45.5%
Tracked investors reporting AVTX
- Steve CohenMar 31, 2026Point72 Asset ManagementShares916.1KValue$13.7M% Portfolio0.02%
- Izzy EnglanderMar 31, 2026Millennium ManagementShares835.5KValue$12.5M% Portfolio0.01%
- Ken GriffinMar 31, 2026Citadel AdvisorsShares260.5KValue$3.9M% Portfolio0.00%
Recent activity
- $12MFeb 17, 2026
- $12.5MMay 15, 2026
- New$11.4MFeb 17, 2026
- New$3.9MMay 15, 2026
- New$13.7MMay 15, 2026
- New$6.3MNov 14, 2025
Frequently asked questions
- How many institutional investors hold AVTX?
- 3 tracked institutional investors disclosed a position in AVTX (AVALO THERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of AVTX?
- Steve Cohen, Point72 Asset Management, holds the largest disclosed position in AVTX, valued at $14M.
- Did institutional ownership of AVTX increase or decrease?
- Across recent 13F filings, tracked investors recorded 6 new positions, 0 increased, 0 reduced, and 0 fully exited AVTX.
- Where does this AVTX ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.